# A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

> **NCT06979453** · PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 366 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Deucravacitinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06979453
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2029-10-12
- **Final completion:** 2034-08-12
- **Target enrollment:** 366 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06979453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06979453, "A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06979453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*